You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • 419 Pembrolizumab + lenvatinib in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC: Phase 1b/2 KEYNOTE-365 cohorts E/F

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
419 Pembrolizumab + lenvatinib in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC: Phase 1b/2 KEYNOTE-365 cohorts E/F
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Kramer G, Shore N, Joshua A, et al
419 Pembrolizumab + lenvatinib in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC: Phase 1b/2 KEYNOTE-365 cohorts E/F
Journal for ImmunoTherapy of Cancer 2021;9:doi: 10.1136/jitc-2021-SITC2021.419